Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Jan 2020
Historique:
received: 29 10 2019
revised: 14 01 2020
accepted: 20 01 2020
entrez: 26 1 2020
pubmed: 26 1 2020
medline: 7 10 2020
Statut: epublish

Résumé

Members of the carbonic anhydrase family are functionally involved in the regulation of intracellular and extracellular pH in physiological and pathological conditions. Their expression is finely regulated to maintain a strict control on cellular homeostasis, and it is dependent on the activation of extracellular and intracellular signaling pathways. Combining RNA sequencing (RNA-seq), NanoString, and bioinformatics data, we demonstrated that the expression of carbonic anhydrase 12 (CAXII) is significantly different in luminal and triple negative breast cancer (BC) models and patients, and is associated with the activation of an epithelial mesenchymal transition (EMT) program. In BC models, the phorbol ester 12-myristate 13-acetate (PMA)-mediated activation of protein kinase C (PKC) induced a down-regulation of CAXII with a concomitant modulation of other members of the transport metabolon, including CAIX and the sodium bicarbonate cotransporter 3 (NBCn1). This is associated with a remodeling of tumor glycolytic metabolism induced after PKC activation. Overall, this analysis highlights the dynamic nature of transport metabolom and identifies signaling pathways finely regulating this plasticity.

Identifiants

pubmed: 31979064
pii: ijms21030715
doi: 10.3390/ijms21030715
pmc: PMC7037142
pii:
doi:

Substances chimiques

Antigens, Neoplasm 0
Sodium-Bicarbonate Symporters 0
Protein Kinase C EC 2.7.11.13
CA13 protein, human EC 4.2.1.1
Carbonic Anhydrases EC 4.2.1.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Références

Front Physiol. 2017 Jul 27;8:544
pubmed: 28798698
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Front Physiol. 2013 Oct 10;4:291
pubmed: 24133456
Cancer Cell. 2013 Sep 9;24(3):347-64
pubmed: 24029232
Nat Commun. 2019 Sep 2;10(1):3840
pubmed: 31477698
Cancer Res Treat. 2016 Jan;48(1):125-32
pubmed: 25761481
Trends Cancer. 2016 Jan;2(1):35-48
pubmed: 28741499
Oncogene. 2013 Oct 31;32(44):5210-9
pubmed: 23208505
PLoS One. 2011 Mar 21;6(3):e17911
pubmed: 21445301
Cell Death Dis. 2017 Apr 6;8(4):e2732
pubmed: 28383555
EMBO Rep. 2007 Jan;8(1):70-6
pubmed: 17159920
Elife. 2018 May 29;7:
pubmed: 29809145
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Mar;1864(3):344-357
pubmed: 30578966
Nat Rev Cancer. 2017 Oct;17(10):577-593
pubmed: 28912578
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
BMC Cancer. 2016 Mar 18;16:236
pubmed: 26988558
Cancer Res. 2008 May 1;68(9):3505-15
pubmed: 18451179
FEBS Lett. 2006 Oct 16;580(24):5647-52
pubmed: 16996503
Cancer Metastasis Rev. 2019 Jun;38(1-2):65-77
pubmed: 31076951
Biochim Biophys Acta. 2015 May;1849(5):506-16
pubmed: 24704206
Nat Cell Biol. 2012 May 13;14(6):567-74
pubmed: 22581054
J Biol Chem. 2012 Jan 27;287(5):3392-402
pubmed: 22170054
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Metabolites. 2018 Feb 28;8(1):
pubmed: 29495652
Br J Cancer. 2003 Apr 7;88(7):1065-70
pubmed: 12671706
Nat Med. 2015 Sep;21(9):998-1009
pubmed: 26236991
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Oncogene. 2018 Oct;37(41):5569-5584
pubmed: 29907770
Trends Endocrinol Metab. 2015 Sep;26(9):453-4
pubmed: 26277479
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
PLoS One. 2018 Jul 2;13(7):e0199476
pubmed: 29965974
Cancer Res. 2003 Nov 1;63(21):7158-66
pubmed: 14612509

Auteurs

Daniele Vergara (D)

Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy.
Laboratory of Clinical Proteomics, "Giovanni Paolo II" Hospital, 73100 ASL-Lecce, Italy.

Sara Ravaioli (S)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Eugenio Fonzi (E)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Loredaria Adamo (L)

Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy.
Laboratory of Clinical Proteomics, "Giovanni Paolo II" Hospital, 73100 ASL-Lecce, Italy.

Marina Damato (M)

Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy.
Laboratory of Clinical Proteomics, "Giovanni Paolo II" Hospital, 73100 ASL-Lecce, Italy.

Sara Bravaccini (S)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Francesca Pirini (F)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Antonio Gaballo (A)

CNR-NANOTEC, Institute of Nanotechnology c/o Campus Ecotekne, 73100 Lecce, Italy.

Raffaela Barbano (R)

Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia, 71013 San Giovanni Rotondo, Italy.

Barbara Pasculli (B)

Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia, 71013 San Giovanni Rotondo, Italy.

Julien Franck (J)

Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Université de Lille, INSERM, U1192 F-59000 Lille, France.

Isabelle Fournier (I)

Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Université de Lille, INSERM, U1192 F-59000 Lille, France.

Michel Salzet (M)

Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Université de Lille, INSERM, U1192 F-59000 Lille, France.

Michele Maffia (M)

Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy.
Laboratory of Clinical Proteomics, "Giovanni Paolo II" Hospital, 73100 ASL-Lecce, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH